Folinic Acid (CF)/5-Fluorouracil (FUra) Combinations in Advanced Gastrointestinal Carcinomas
H. Wilke(Kliniken Essen-Mitte), H. Poliwoda, Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), U. Fink(Technical University of Munich), Hans‐Joachim Schmoll(Martin Luther University Halle-Wittenberg), H.-J. Meyer(Medizinische Hochschule Hannover), A.-R. Hanauske, C. Schöber, H. Link(Medizinische Hochschule Hannover), P. Preusser(University Hospital Münster), M. Freund, W. Achterrath(Messer (Germany))
Cited by 1
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial
|The Lancet Oncology|2007|808
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|The Lancet Oncology|2012|526
Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction
|Journal of Clinical Oncology|2006|464
Time Course of Tumor Metabolic Activity During Chemoradiotherapy of Esophageal Squamous Cell Carcinoma and Response to Treatment
|Journal of Clinical Oncology|2004|460